Neurotoxins, parkinsonism and Parkinson's disease

Pharmacology and Therapeutics

Volumn 32, Issue 1, 1987, Pages 19-49

  William Langston, J ^a   Irwin, Ian ^a   Ricaurte, George A ^b  

^a CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBON DISULFIDE; LEVODOPA; MANGANESE; METHAMPHETAMINE; NEUROTOXIN; OXIDOPAMINE;

BASAL GANGLION; CENTRAL NERVOUS SYSTEM; DRUG THERAPY; ETIOLOGY; HUMAN; INTOXICATION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; REVIEW; THERAPY;

ANIMAL; CATS; DISEASE MODELS, ANIMAL; DOGS; HUMAN; MACACA MULATTA; MICE; NEUROTOXINS; PARKINSON DISEASE, SECONDARY; RATS;

EID: 0023251916     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(87)90062-3     Document Type: Article

References (190)

1. 2 poisoning in animals and man
2. Brain peroxidase and catalase in Parkinson's disease
3. Intoxication by manganese in Chile (study on 64 Cases) I. Environmental and etiological factors
4. Manganese, superoxide dismutase and oxygen tolerance in some lactic acid bacteria
5. Report on an autopsy case of chronic manganese poisoning
6. Active oxygen species and the functions of phagocytic leukocytes
7. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases
8. Manganese and extrapyramidal disorders
9. Etiology of Parkinson's disease: A research strategy
10. Environmental and genetic factors in the etiology of Parkinson's disease
11. The role of oxygen and its derivatives in microbial pathogenesis and host defense
12. A critical review of the literature on carbon disulfide toxicity
13. Verhalten der Monoaminoxydase im Gehirn des Menschen Nach Therapie Mit Monoaminoxdase-hemmern
14. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations
15. Structure-activity relationships of amphetamine and derivatives
16. Fine structural changes in brain after intracisternal injection of 6-hydroxydopamine
17. The striatonigral degenerations. Putaminal pigments and nosology
18. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine: Evidence for selective degeneration of catecholaminergic neurons
19. Enzymatic metabolism of drugs and other foreign compounds
20. Biochemistry of oxygen radical species
21. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by MPTP
22. Paraquat: Model for oxidant-initiated toxicity
23. Observations relating to the cause of Parkinson's disease: PET scans after MPTP
24. Chronic manganese poisoning Report of a case with autopsy
25. The occurrence, distribution and physiologic role of catecholamines in the nervous system
26. Perspectives
27. 3,4-Dihydroxyphenylaline and 5-hydroxytryptophan as reserpine antagonists
28. An unusual form of mineral poisoning affecting the nervous system: manganese
29. Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine
30. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
31. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes
32. The pathobiology of Parkinson's disease: Biochemical aspects of dopamine neuron senescence
33. Prevention of 6-hydroxydopamine neurotoxicity
34. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1236-tetrahydropyridine (MPTP) in monkeys
35. Biochemical mechanisms in chronic carbon disulfide poisoning
36. Pharmacological implications of microsomal enzyme induction
37. Chronic manganese intoxication
38. 1-Methyl-4-phenyl-1236-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate
39. Manganese in health and disease
40. Aromatic amino acids and modification of parkinsonism
41. On the effects of black oxide of manganese when inhaled into the lungs
42. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
43. Incidents which develop in rubber workers—Inhalation of carbon disulfide vapors
44. Lack of a high affinity transport system for dopamine in the median eminence and posterior pituitary
45. Enhanced autoxidation of dopamine as a possible basis of manganese neurotoxicity
46. Free-radical oxidation and antioxidants
47. An approach to free radicals
48. Verteilung von Noradrenalin und Dopamin (3-hydroxytyramin) im Gehrin des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems
49. Structural and biochemical alterations in dopaminergic innervation of the caudate following continuous amphetamine administration
50. Fluctuations of disability in Parkinson's disease: Pathophysiology
51. Altered sensitivity to d-methamphetamine, apomorphine and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methamphetamine
52. Chronic manganese poisoning in an ore crushing mill
53. Pathology of parkinsonism. A preliminary report of 24 cases
54. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): Relationship to parkinsonism
55. Pathology of Parkinson's disease
56. Neuropathology of MPTP-treated monkeys: Comparison with the neuropathology of human idiopathic Parkinson's disease
57. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
58. The effect of age on the activity and molecular properties of human brain monoamine oxidase
59. Superoxide dismutases
60. Superoxide dismutase in the nervous system
61. Effects of amfonelic acid, a-methyltyrosine, ro 4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
62. Subcellular distribution of D-amino acid oxidase and catalase in rat brain
63. Carbonyl sulfide: Potential agent of atmospheric sulfur corrosion
64. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
65. Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease
66. In vitro evidence that covalent cross-linking of neurofilament occurs in gamma-diketone neuropathy
67. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro
68. Heavy metals and the nervous system
69. Effects of amphetamines in humans
70. Uber die Katalyse des Hydroperoxydes
71. Manganese ions, oxidation reactions and the superoxide radical
72. Reserpine-resistant uptake of catecholamines in isolated tissues of the rat
73. Neuronal degeneration in rat brain induced by 6-hydroxydopamine: A histological and biochemical study
74. Inhibition of amine uptake by hydrogen peroxide: A mechanism for the toxic effects of 6-hydroxydopamine
75. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate
76. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: Relationships between monoamine oxidase, MPTP metabolism and neurotoxicity
77. Protection against the neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
78. Alloxan-induced diabetes—Evidence for hydroxyl radical as a cytotoxic intermediate
79. Metabolism of brain dopamine in human parkinsonism: Neurochemical and clinical aspects
80. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain
81. Norepinephrine, epinephrine and the sympathomimetic amines
82. Selective accumulation of MPP + in the substantia nigra: A key to neurotoxicity?
83. Total iron and manganese in the piestic ground waters in the main artesian wells at Takamatsu city
84. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
85. Pharmacological aspects of the chewing of Khat leaves
86. Intoxication by manganese in well water
87. Nature of underground water in Japan
88. Spectrographic determination of trace elements in lake waters of northern maine
89. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels
90. Mechanisms of neurotoxicity of MPTP
91. Pharmacological actions of 6-hydroxydopamine
92. Cd and Mn in streams of the upper Iwaki river
93. Use of 6-hydroxydopamine to deplete brain catecholamines in the rhesus monkey: Effects on urinary metabolites and behavior
94. Action of carbon disulfide on the central nervous system
95. MPTP and Parkinson's disease
96. The promise of a newly described neurotoxin
97. MPTP-induced parkinsonism: How good a model is it?
98. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Implications for treatment and the pathophysiology of Parkinson's disease
99. MPTP: Current concepts and controversies
100. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
101. Selective nigral toxicity after systemic administration of MPTP in the squirrel monkey
102. Pargyline prevents MPTP-induced parkinsonism in primates
103. 1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra
104. Neurological, medical and biochemical signs and symptoms indicating chronic industrial carbon disulfide absorption
105. Brain enzyme is the target of drug toxin
106. Paralysis agitans. I. Pathologische Anatomie
107. The effects of carbon disulfide exposure on brain catecholamins in rats
108. Possible role of neuromelanin in the pathogenesis of Parkinson's disease
109. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
110. Biochemical and morphological investigations on nervous tissues of rats inhaling carbon disulfide
111. Neurochemical investigations in vitro with 1-methyl-4-phenyl-1236-tetrahydropyridine (MPTP) in preparations of rat brain
112. Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)
113. Partition of Manganese among organs and intracellular organelles in the rat
114. Superoxide dismutase: A history
115. A proposed mechanism of the action of carbon disulfide on dopamine-beta-hydroxylase
116. Carbon disulfide II. A proposed mechanism for the action of carbon disulfide on dopamine-beta-hydroxylase
117. Supression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-dopa
118. Modification of chronic manganese poisoning: Treatment with L-DOPA or 5-OH Tryptamine
119. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus ceruleus
120. Metabolic activation of drugs to toxic substances
121. Drug metabolism as a cause of drug toxicity
122. Acetaminophen induced hepatic necrosis IV. The role of glutathione
123. Amphetamines: Biochemical and behavioral actions in animals
124. A study of the manganese content in daily food consumption in Japan
125. Studies on trace elements in food and beverages. III. Manganese content in green tea
126. Role of oxygen-dependent mechanisms in antibody-induced lysis of tumor cells by activated macrophages
127. Changes in monoamine oxidase with aging
128. Manganese toxicity: Effects of L-DOPA and pargyline treatments
129. On the clinical and pathological anatomy in chronic manganese poisoning
130. Subcellular localization of superoxide dismutase in rat liver
131. Partial protection from the dopaminergic neurotoxin n-methyl-4-phenyl-1,2,3,6-terrahydropyridine by four different antioxidants in the mouse
132. Extrapyramidal symptoms from carbon disulfide exposure in grain storage workers
133. The treatment of acetaminophen poisoning
134. 2
135. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP to its active metabolite, MPP+
136. Carbonyl sulfide and carbon disulfide from the eruptions of Mount St. Helens
137. Behavior of free-ranging macaques after intraventricular administration of 6-hydroxydopamine
138. Dopamine nerve terminal degeneration produced by high doses of methamphetamine in the rat brain
139. Nerve terminal degeneration after a single injection of d-amphetamine in iprindole-treated rats: Relation to selective long-lasting dopamine depletion
140. Dopamine uptake blockers protect against the dopamine depleting effects of MPTP in the mouse striatum
141. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment
142. Long-term effects of repeated methamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study
143. Further evidence that amphetamines produce long-lasting dopaminergic neurochemical deficits by destroying dopamine nerve fibers
144. Degeneration of the basal ganglia in monkeys from chronic carbon disulfide poisoning
145. Neurochemical insights into monoamine oxidase inhibitors with special reference to deprenyl (selegiline)
146. Relationship of sex and aging to monoamine oxidase activity of human brain, plasma and platelets
147. Chronic manganism. Neurological and laboratory studies during treatment with levodopa
148. Meperidine analog exposure in California narcotics abusers: Initial epidemiologic findings
149. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase A and B and suicide inactivation of the enzymes by MPTP
150. Model experiments on the molecular mechanism of action of 6-hydroxydopamine
151. Superoxide dismutase and glutathione peroxidase activities in rat brain
152. Mechanism of induction of Parkinson disease by 1-methyl-4-phenyl-1236-tetrahydropyridine (MPTP) Chemical and electrochemical characterization of a geminal-dimethyl-blocked analog of a postulated toxic metabolite
153. Experimental carbon disulfide poisoning in rabbits—Its mechanism and similarities with human case report
154. Lack of evidence supporting a role for dopamine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
155. Essential trace elements in man; manganese, a study on homeostasis
156. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methamphetamine
157. Long-term methamphetamine-induced changes in brain catecholamines in tolerant rhesus monkeys
158. Carbon Disulfide
159. Neurophysiological findings in chronic carbon disulfide poisoning: a descriptive study
160. Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid
161. MPTP: A neurotoxin relevant to the pathophysiology of Parkinson's disease
162. Histopathology of the brain resulting from manganese poisoning
163. Drug-induced parkinsonism in the elderly
164. Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: Time-course and time-dependent interactions with amfonelic acid
165. Long-term effects of continuous exposure to amphetamine on brain dopamine concentration and synaptosomal uptake in mice
166. The biological fate of reserpine
167. Oxidation and phosphorylation processes in brain mitochondria of rats exposed to carbon disulfide
168. Hazards to health: Manganese
169. New advances in the toxicology of carbon disulfide
170. The pharmacology of 6-hydroxydopamine
171. An electron microscopic study of selective acute degeneration of sympathetic nerve terminals after administration of 6-hydroxydopamine
172. Contribution à l'étude de l'anatomie pathologique du locus niger de soemmering avec quelques déductions relatives à la pathogenic des troubles du tonus musculair et de la maladie de parkinson
173. 6-Hydroxydopamine-induced degeneration of central monoaminergic neurons
174. On the role of pyridoxamine in the mechanism of the toxic action of carbon disulfide
175. Carbon disulphide poisoning in viscose rayon factories
176. Progressive bulbar paralysis and amyotrophic lateral sclerosis from chronic manganese poisoning
177. Spinal cord and peripheral nervous system in chronic manganese poisoning
178. Ascorbic acid reduces the dopamine depletion induced by MPTP
179. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine
180. Drugs that inhibit adrenergic nerves and block adrenergic receptors
181. Distinct monoamine oxidase A and B populations in primate brain
182. A parkinson-like neurologic deficit in primates is caused by a novel 4-substituted tetrahydropyridine
183. Iron, zinc, free radicals and oxygen in tissue disorders and cancer control
184. The prevention of manganese poisoning
185. 1-Methyl-4-phenyl-(2′-methylphenyl)-1236-tetrahydropyridine [2′CH3MPTP] is a more potent dopaminergic neurotoxin than MPTP in mice